<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624242</url>
  </required_header>
  <id_info>
    <org_study_id>2022PI03935</org_study_id>
    <nct_id>NCT05624242</nct_id>
  </id_info>
  <brief_title>Assessment of Right Ventricular Function by Cardiac MRI in Patients With Pulmonary Arterial Hypertension (IRMA)</brief_title>
  <acronym>IRMA</acronym>
  <official_title>Assessment of Right Ventricular Function by Cardiac Magnetic Resonance Imaging in Patients With Pulmonary Arterial Hypertension (IRMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension (PH) is a pathophysiological condition defined by an increase in&#xD;
      pulmonary arterial pressure above 20mmHg, which encompasses many very dissimilar conditions.&#xD;
      Right ventricular function is the major determinant of survival in these patients. Currently,&#xD;
      right ventricular function is estimated by trans-thoracic echocardiography via the&#xD;
      measurement of standardised parameters. However, cardiac magnetic resonance imaging is now&#xD;
      the reference technique for non-invasive quantification of volumes, mass, function of the&#xD;
      right ventricle but can also be useful for the consideration of the pulmonary circulation.&#xD;
      Thus, indices of function can be extracted and it plays an increasing role in the prognostic&#xD;
      evaluation of the right heart function at diagnosis and at re-evaluation under treatment of&#xD;
      pulmonary arterial hypertension. This work will initially focus on the assessment of right&#xD;
      ventricular myocardial work by echocardiography and cardiac magnetic resonance imaging in&#xD;
      comparison with invasive haemodynamic data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Transplantation-free survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cardiac magnetic resonance imaging</intervention_name>
    <description>all patients had magnetic resonance imaging at baseline and during follow-up.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population concerns patients with pulmonary arterial hypertension followed up in&#xD;
        our centre, at diagnosis and when starting vasodilator treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with pulmonary arterial hypertension (group 1)&#xD;
&#xD;
          -  Patient with cardiac MRI, echocardiography and right heart catheterisation within 1&#xD;
             month of each other&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with features of venous/capillary involvement&#xD;
&#xD;
          -  Pulmonary arterial hypertension associated with with congenital heart disease&#xD;
&#xD;
          -  Patient's decline to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon Valentin, MD</last_name>
    <phone>+3383153272</phone>
    <email>s.valentin@chru-nancy.fr</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

